EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leuke... (sident Research commented onthe results ...)

EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models

Date:12/10/2007

sident, Research, commented on the results, "We continue to be encouraged by the potent preclinical antitumor activity of ENMD-1198 as a single agent and in combination with other chemotherapeutics. The observation that two active microtubule agents can be combined to produce synergistic activity at tolerated doses is quite encouraging. ENMD-1198 is currently being evaluated in a Phase 1 study in refractory solid tumor patients and we anticipate commencement of Phase 2 clinical studies in 2008."

To view the poster presentation, visit the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (includi
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3
Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
7. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
8. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
9. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
10. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
11. Retirement Living TV Presents Sex, Drugs and Rock N Roll

Post Your Comments:

(Date:12/5/2009)WASHINGTON, Dec. 5 ,, What: Cuts for a Cause ,, Why: To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given

(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int

(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for

(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W

(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s

[0] Salon Leau to Host 'Cuts for a Cause' to Raise Funds and Spread the Word About Childhood Terminal Illnesses [0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders [0] Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification [0] Distributor Announces New Applications for Wind Turbines [0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children

...daq: XTNT ) today reported financial results for ...7., The company reported a net loss and net loss ...on, or $0.52 per share, for the fourth quarter,of ...mpany,s net loss per share attributable to common ...

... same results, analysis shows , , TUESDAY,...cular advantage to any single treatment for acute ...ion that carries with it a high risk of death, Can...or another, according to a report in the Feb. 20 ...

... way to spot hearing problems, study finds, , ...s may not just be a window to the soul, they may a...r senses. , A new study reports that the eyes can ... young children and in people who can,t actively t...

...tive isotopes for peacetime uses at Oak Ridge Nati...al Historic Chemical Landmark by the American Chem...enn., on March 6. , Bruce E. Bursten, Ph.D., pre...s, which began in 1946, demonstrated the peaceful ...

... Hospital, WALLA WALLA, Wash., Feb. 19 Secretary...today the Department of,Veterans Affairs (VA) will...on facility focused on mental health at the Walla ...ortance of mental,health as an issue for our veter...

...ered physical or sexual abuse as children spend up...ts, according to a long-term study of more than 3,...these women used health services at significantly ...quences from abuse that occurred decades ago, said...

Other Medicine News:Health News:XTENT Announces 2007 Financial Results 2 Health News:XTENT Announces 2007 Financial Results 3 Health News:XTENT Announces 2007 Financial Results 4 Health News:XTENT Announces 2007 Financial Results 5 Health News:XTENT Announces 2007 Financial Results 6 Health News:No Difference Found in Treatments for Acute Kidney Failure 2 Health News:No Difference Found in Treatments for Acute Kidney Failure 3 Health News:Eyes a Window to Hearing Loss? 2 Health News:Eyes a Window to Hearing Loss? 3 Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 2 Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 3 Health News:Women who suffered child abuse spend more on health care 2 Health News:Women who suffered child abuse spend more on health care 3

XTENT Announces 2007 Financial Results No Difference Found in Treatments for Acute Kidney Failure Eyes a Window to Hearing Loss?Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark VA Secretary Announces New Walla Walla Facility Women who suffered child abuse spend more on health care

(Date:12/4/2009)EMERYVILLE, Calif., Dec. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data present

(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received

(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V

Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2 Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2 Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2 Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3 Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4 drugstore com Continues Global Sales Expansion to More Than 3 5 Billion International Consumers 62432 1 drugstore com Continues Global Sales Expansion to More Than 3 5 Billion International Consumers 62432 2 Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 15043 1 Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 15043 2 Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 15043 3 Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 15041 1 Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 15041 2

[0] Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference [0] Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care [0] Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers

...acell Corporation,(Nasdaq: ACEL ) today announced...eutics (2008; 7(7):1871-9) reports that a combinat...ione antidiabetic drug rosiglitazone,shows a promi...of,PI3K-dependent Fra-1 expression or Survivin., ...earch conducted at,the University of Vermont in Bu...

...cal Course of Alzheimer,s Disease; Patients, Exper...emory and Thinking, Activities of Daily Livin..., July 17 Medivation, Inc.,(Nasdaq: MDVN ) today...,Alzheimer,s disease pivotal clinical trial of the... issue of The Lancet. In this double-blind,placebo...

Other Medicine Technology:Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines 2 Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines 3 Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease 2 Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease 3 Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease 4 Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease 5

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease

...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...

Medicine Products:

Hexosaminidase A & Total, Serum Hexagonal Phospholipid Neutralization Heterophile Antibody by Latex Agglutination with Reflex to Titer Heterophile Antibody (Mononucleosis)

EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leuke...(sident Research commented onthe results ...),Health